CN1682818A - Fleabane and earthworm dripping pill and its preparing method - Google Patents
Fleabane and earthworm dripping pill and its preparing method Download PDFInfo
- Publication number
- CN1682818A CN1682818A CNA2005100086200A CN200510008620A CN1682818A CN 1682818 A CN1682818 A CN 1682818A CN A2005100086200 A CNA2005100086200 A CN A2005100086200A CN 200510008620 A CN200510008620 A CN 200510008620A CN 1682818 A CN1682818 A CN 1682818A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- substrate
- fleabane
- earthworm
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 65
- 241000132521 Erigeron Species 0.000 title claims abstract description 40
- 241000361919 Metaphire sieboldi Species 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 22
- 239000003814 drug Substances 0.000 claims abstract description 117
- 238000002360 preparation method Methods 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 93
- 229920001223 polyethylene glycol Polymers 0.000 claims description 93
- 239000000843 powder Substances 0.000 claims description 81
- 239000000758 substrate Substances 0.000 claims description 43
- 229920002472 Starch Polymers 0.000 claims description 37
- 235000019698 starch Nutrition 0.000 claims description 37
- 239000008107 starch Substances 0.000 claims description 37
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 35
- -1 polyoxyethylene stearate Polymers 0.000 claims description 35
- 239000011734 sodium Substances 0.000 claims description 35
- 229910052708 sodium Inorganic materials 0.000 claims description 35
- 229920000858 Cyclodextrin Polymers 0.000 claims description 32
- 239000001116 FEMA 4028 Substances 0.000 claims description 32
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 32
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 32
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 32
- 229960004853 betadex Drugs 0.000 claims description 32
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 32
- 229920001983 poloxamer Polymers 0.000 claims description 32
- 229960000502 poloxamer Drugs 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 31
- 241000237636 Pheretima Species 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- 235000019634 flavors Nutrition 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
- 239000001828 Gelatine Substances 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 235000015424 sodium Nutrition 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000007493 shaping process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 14
- 239000002775 capsule Substances 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 231100001231 less toxic Toxicity 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000470 constituent Substances 0.000 description 38
- 238000012360 testing method Methods 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 10
- 239000000969 carrier Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 6
- 239000000428 dust Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000015250 liver sausages Nutrition 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 241001640034 Heteropterys Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The fleabane-earthworm dripping pill is a kind of oral medicine composition preparation with the functions of promoting blood circulation and dredging meridian passage for treating ischemic apoplexy, etc. It is developed on the basis of available fleabane-earthworm capsule and has high bioavailability, fast medicine release, fast acting, high effective component content, low cost and less toxic side effect, and the production process has no pollution. The fleabane-earthworm dripping pill is prepared with fleabane and earthworm as Chinese medicine material and matrix carrier.
Description
Technical field
The present invention relates to a kind of promoting blood circulation to remove obstruction in the collateral effect that has, the pharmaceutical composition that is used for the treatment of the diseases such as cerebral infarction that obstruction of collaterals by blood stasis causes, be particularly related to based on Chinese traditional patent formulation fleabane and earthworm capsule, change a social system a kind of drug composition oral dropping pill formulation that forms through dosage form.
Background technology
The fleabane and earthworm capsule that is prepared from according to the prescription that provides among the national drug standards WS-10424 (ZD-0424)-2002 and preparation technology, it is a kind of promoting blood circulation to remove obstruction in the collateral effect that has, the oral Chinese medicine preparation that is used for the treatment of the symptoms such as cerebral infarction that obstruction of collaterals by blood stasis causes, through clinical verification, steady quality, determined curative effect is the common drug preparation that clinical and family is used for the treatment of above disease.Below be prescription and the preparation technology who provides among the drug standard WS-10424 (ZD-0424)-2002:
Prescription: fresh Pheretima 1200g, Herba Erigerontis 1000g, starch 80g;
Method for making: above two flavor medical materials, get fresh Pheretima and add water logging and washed 1～2 hour, after cleaning, smash to pieces, homogenate 10～15 minutes, centrifugal with the sodium chloride solution extraction of 0.1mol/L 6 hours, get supernatant, cold drying, Pheretima extract is standby.Get Herba Erigerontis, use Diluted Alcohol heating and refluxing extraction 50 minutes, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.25～1.35 (60 ℃), and hydro-oxidation sodium filters to alkalescence, filtrate adds hydrochloric acid and regulates pH value to 2.0, filters, and precipitate is extremely neutral with hot water wash, drain, after a small amount of Diluted Alcohol gradation washing, add an amount of thermosol of ethanol, adding medicinal activated carbon decolours in right amount, filter, filtrate concentrates, and places, separate out amorphous yellow powder, filter, drying is with Pheretima extract, starch, mixing, sieve, 1000 capsules of packing into, promptly.
In the appended fleabane and earthworm capsule description this kind is explained as follows:
Nomenclature of drug: fleabane and earthworm capsule;
Main component: fresh Pheretima, Herba Erigerontis;
Function cures mainly: promoting blood circulation to remove obstruction in the collateral.Be used for the cerebral infarction that obstruction of collaterals by blood stasis causes.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Summary of the invention
Purpose of the present invention, be to replenish the existing deficiency that is used for the treatment of the oral drug preparation of the symptoms such as cerebral infarction that obstruction of collaterals by blood stasis causes, a kind of bioavailability height is provided, release fast, quick produce effects, toxic and side effects is little, and medicament contg height, taking convenience, cheap, and in preparation process free of contamination drug composition oral preparation fleabane and earthworm dripping pill.
Fleabane and earthworm dripping pill involved in the present invention is a raw material with the extract that contains 2 flavor Chinese medicine active pharmaceutical ingredients such as fresh Pheretima and Herba Erigerontis, is prepared from the pharmaceutically suitable carrier as substrate.Be prepared by the following technical solutions, can obtain fleabane and earthworm dripping pill involved in the present invention:
[preparation method]
1. be unit with g or kg, calculate, get 6 parts of fresh Pheretimas according to weight, 5 parts of Herba Erigerontiss, more than two flavors to make the extract that contains 2 flavor Chinese medicine active pharmaceutical ingredients such as fresh Pheretima and Herba Erigerontis in advance standby;
2. substrate---Polyethylene Glycol
(1000,2000,4000,6000,8000,10000,20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning---with g or kg is unit, by weight, and medicine dry powder: substrate=1: 1～1: 9.
4. according to the given ratio of prescription, accurately take by weighing medicine dry powder and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing medicine dry powder and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine (as the TZDW-1 type drop pill machine of Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production), and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on (50～100) ℃, the temperature cooling of condensing agent also remains on (40～-5) ℃;
6. when treating in dropping-pill machine head and the condensation column that the temperature of condensing agent reaches desired state of temperature respectively, will contain fused solution and/or the emulsion and/or the suspension of medicine dry powder and substrate, place in the water dropper jar of drop pill machine, splash in the condensing agent;
Condensing agent can be any one in liquid paraffin, methyl-silicone oil, the vegetable oil;
7. will shrink the drop pill taking-up of molding by the outlet of drop pill machine, remove the surface condensation agent, be drying to obtain.
[appendix: contain 2 flavor Chinese medicine active pharmaceutical ingredient preparation method of extract such as fresh Pheretima and Herba Erigerontis] is unit with g or kg, according to the weight portion meter, gets 6 parts of fresh Pheretimas, 5 parts of Herba Erigerontiss, more than two the flavor medical materials, fresh Pheretima adds water logging and washed 1～2 hour, after cleaning, smash homogenate 10～15 minutes, the sodium chloride solution extraction of usefulness 0.1mol/L 6 hours to pieces, centrifugal, get supernatant, cold drying, it is standby to get Pheretima extract.Get Herba Erigerontis, use Diluted Alcohol heating and refluxing extraction 50 minutes, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.25～1.35 (60 ℃), hydro-oxidation sodium filters to alkalescence, and filtrate adds hydrochloric acid and regulates pH value to 2.0, filter, precipitate, is drained to neutral with hot water wash, after a small amount of Diluted Alcohol gradation washing, add an amount of thermosol of ethanol, add medicinal activated carbon and decolour in right amount, filter, filtrate concentrates, place, separate out amorphous yellow powder, filter drying, with the Pheretima extract mixing, be dried and crushed into dry powder promptly through decompression (0.1Mpa) low temperature (60 ℃) again.
What provide above is a kind of preparation method of common drug extract, under the same or analogous prerequisite of main active pharmaceutical ingredient of extract, is not limited to this a kind of method.
Beneficial effect
The fleabane and earthworm capsule that is prepared from according to the prescription that provides among the national drug standards WS-10424 (ZD-0424)-2002 and preparation technology, it is a kind of promoting blood circulation to remove obstruction in the collateral effect that has, the oral Chinese medicine preparation that is used for the treatment of the symptoms such as cerebral infarction that obstruction of collaterals by blood stasis causes, through clinical verification, steady quality, determined curative effect is the common drug preparation that clinical and family is used for the treatment of above disease.Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.And that the syrups preparation also exists medicament contg is low, and taking dose is big, and taking dose is inaccurate, takes inconvenient characteristics, also is not easy to go out to carry wait deficiency.In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Fleabane and earthworm dripping pill involved in the present invention is compared with the fleabane and earthworm capsule has following beneficial effect:
1. fleabane and earthworm dripping pill involved in the present invention; utilize surfactant to be substrate; make solid dispersion with the extract that contains two flavor Chinese medicine active pharmaceutical ingredients such as fresh Pheretima, Herba Erigerontis; making medicine be molecule, colloid or microcrystalline state is scattered in the substrate; the total surface area of medicine increases; and substrate is hydrophilic; medicine had wetting action; can make medicine molten microgranule or the solution of loosing into rapidly; thereby make the dissolving of medicine and absorb quickening; thereby improved bioavailability, brought into play efficient, quick-acting effects etc.Compare with the capsular administering mode of fleabane and earthworm, exist essential distinction.Utilize the drop pill of solid dispersion technology preparation, can adopt oral and sublingual administration, effective ingredient is fully contacted with mucomembranous surface, absorb, directly enter blood circulation by mucomembranous epithelial cell.Because active constituents of medicine directly enters blood circulation without gastrointestinal tract and liver, avoided first pass effect effectively, also avoided gastrointestinal irritation, thereby thereby it is rapid to make that fleabane and earthworm dripping pill involved in the present invention has an onset, the bioavailability height, characteristics such as side effect is little, and medication is convenient.
2. fleabane and earthworm dripping pill involved in the present invention contacts promptly with saliva and to dissolve rapidly, and is absorbed by oral mucosa, and is not only rapid-action, and the influence of not taken food, and promptly all can containing take after meal ante cibum.
3. fleabane and earthworm dripping pill involved in the present invention mixes the extract that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
4. production technology, the equipment of preparation drop pill are simple, easy to operate, the automaticity height, and labor intensity is low, the production efficiency height.Workshop does not have dust simultaneously, helps labor protection and environmental protection yet.
5. the production cost of preparation drop pill is usually with about 50% of other oral formulations of kind, and compares with oral liquid, and the dosage of drop pill is accurate, thereby makes the patient take metering control easily.
In sum, make fleabane and earthworm dripping pill involved in the present invention have the advantage of triple effect (quick-acting, efficient, long-acting), three little (taking dose is little, toxicity is little, side effect little), five convenience (convenient for production, store convenience, convenient transportation, easy to carry, easy to use).
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of fleabane and earthworm dripping pill of the present invention.
First group: the test of single-matrix
1. it is standby that the preparation method that provides according to [appendix] makes the extract dry powder that contains fresh Pheretima, two kinds of Chinese medicine active pharmaceutical ingredients of Herba Erigerontis earlier;
2. substrate: Polyethylene Glycol
(1000,2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and medicine dry powder: substrate=1: 1～1: 9;
4. be prepared according to the process of [preparation method] 4～7 again, promptly can make the fleabane and earthworm dripping pill of all size.
[result of the test]
Test 1: for observe the dry powder that contains active constituents of medicine and different substrates when 1: 1 proportioning prepared fleabane and earthworm dripping pill in qualitative difference, according to 1: 1 ratio, the dry powder that will contain active constituents of medicine respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions that dry powder and different substrates constituted experiments that contain active constituents of medicine, and obtain 16 groups of different experimental results and see Table 1.
Test 2: for observe the dry powder that contains active constituents of medicine and different substrates when 1: 3 proportioning prepared fleabane and earthworm dripping pill in qualitative difference, according to 1: 3 ratio, the dry powder that will contain active constituents of medicine respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions that dry powder and different substrates constituted experiments that contain active constituents of medicine, and obtain 16 groups of different experimental results and see Table 2.
Test 3: for observe the dry powder that contains active constituents of medicine and different substrates when 1: 9 proportioning prepared fleabane and earthworm dripping pill in qualitative difference, according to 1: 9 ratio, the dry powder that will contain active constituents of medicine respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions that dry powder and different substrates constituted experiments that contain active constituents of medicine, and obtain 16 groups of different experimental results and see Table 3.
Second group: the test of mixed-matrix
1. it is standby that the preparation method that provides according to [appendix] makes the extract dry powder that contains fresh Pheretima, two kinds of Chinese medicine active pharmaceutical ingredients of Herba Erigerontis earlier;
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate,
Molecular formula is with C
17H
35COO (CH
2CH
2O)
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether,
Molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstach Sodium, starch generates with the monoxone effect under alkali condition,
2.5 betacyclodextrin---English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. (with g or kg is unit to proportioning, by weight)
3.1 the ratio of composite interstitial substance---polyoxyethylene stearate 40 esters: Polyethylene Glycol or poloxamer: poly-ethanol or carboxymethyl starch sodium: Polyethylene Glycol or betacyclodextrin: Polyethylene Glycol=1: 1～1: 10,
3.2 hybrid medicine dry powder: mixed-matrix weight and=1: 1～1: 9,
4. be prepared according to [preparation method] again, promptly can make the fleabane and earthworm dripping pill of various different sizes.
[result of the test]
Test 4: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 1 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 1 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 4.
Test 5: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 3 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 3 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 5.
Test 6: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 9 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 9 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 6.
Test 7: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 1 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 1 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 7.
Test 8: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 3 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 3 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 8.
Test 9: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 9 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 9 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 9.
Test 10: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 1 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 1 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 10.
Test 11: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 3 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 3 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 11.
Test 12: for observe the dry powder that contains active constituents of medicine and mixed-matrix when 1: 9 the proportioning prepared fleabane and earthworm dripping pill in qualitative difference, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, the dry powder that will contain active constituents of medicine according to 1: 9 ratio mixes mutually with 4 kinds of different mixed-matrixes and makes evenly again, adopt homemade drop pill machine, be prepared according to the step of stipulating in the preparation method, can obtain 4 pharmaceutical compositions that dry powder and mixed-matrix constituted experiments that contain active constituents of medicine, and obtain 4 groups of different experimental results and see Table 12.
The group practices of table 1 medicine dry powder and single-matrix
(medicine dry powder: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 2000 | ??50.0 | 64 | ??＜30 | ??＞10 | ??+ |
| Polyethylene Glycol 4000 | ??50.0 | 74 | ??＜30 | ??＞10 | ??++ |
| Polyethylene Glycol 6000 | ??50.0 | 81 | ??＜30 | ??＞10 | ??+++ |
| Polyethylene Glycol 8000 | ??50.0 | 82 | ??＜30 | ??＞10 | ??+++ |
| Polyethylene Glycol 10000 | ??50.0 | 84 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 20000 | ??50.0 | 85 | ??＜30 | ??＜10 | ??+++ |
| Polyoxyethylene stearate 40 esters | ??50.0 | 75 | ??＜30 | ??＞10 | ??++ |
| Betacyclodextrin | ??50.0 | 72 | ??＜30 | ??＞10 | ??++ |
| Poloxamer | ??50.0 | 73 | ??＜30 | ??＞10 | ??++ |
| Carboxymethyl starch sodium | ??50.0 | 71 | ??＜30 | ??＞10 | ??++ |
| Sodium lauryl sulphate | ??50.0 | 69 | ??＜30 | ??＞10 | ??++ |
| Stearic acid | ??50.0 | 57 | ??＜30 | ??＞10 | ??++ |
| Sodium stearate | ??50.0 | 56 | ??＜30 | ??＞10 | ??+++ |
| Glycerin gelatine | ??50.0 | 55 | ??＜30 | ??＞10 | ??+++ |
| Lac | ??50.0 | 54 | ??＞30 | ??＞10 | ??+++ |
The group practices of table 2 medicine dry powder and single-matrix
(medicine dry powder: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 2000 | ??25.0 | ??78 | ??＜30 | ??＞10 | ??++ |
| Polyethylene Glycol 4000 | ??25.0 | ??86 | ??＜30 | ??＜10 | ??++ |
| Polyethylene Glycol 6000 | ??25.0 | ??93 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 8000 | ??25.0 | ??91 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 10000 | ??25.0 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 20000 | ??25.0 | ??91 | ??＜30 | ??＜10 | ??++ |
| Polyoxyethylene stearate 40 esters | ??25.0 | ??92 | ??＜30 | ??＜10 | ??++ |
| Betacyclodextrin | ??25.0 | ??85 | ??＜30 | ??＞10 | ??++ |
| Poloxamer | ??25.0 | ??89 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium | ??25.0 | ??80 | ??＜30 | ??＞10 | ??++ |
| Sodium lauryl sulphate | ??25.0 | ??77 | ??＜30 | ??＞10 | ??++ |
| Stearic acid | ??25.0 | ??76 | ??＞30 | ??＞10 | ??+++ |
| Sodium stearate | ??25.0 | ??72 | ??＞30 | ??＞10 | ??+++ |
| Glycerin gelatine | ??25.0 | ??74 | ??＞30 | ??＞10 | ??+++ |
| Lac | ??25.0 | ??72 | ??＞30 | ??＞10 | ??+++ |
The group practices of table 3 medicine dry powder and single-matrix
(medicine dry powder: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 2000 | ??10.0 | ??85 | ??＜30 | ??＞10 | ??++ |
| Polyethylene Glycol 4000 | ??10.0 | ??93 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 6000 | ??10.0 | ??94 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 8000 | ??10.0 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 10000 | ??10.0 | ??94 | ??＜30 | ??＜10 | ??+++ |
| Polyethylene Glycol 20000 | ??10.0 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Polyoxyethylene stearate 40 esters | ??10.0 | ??93 | ??＜30 | ??＜10 | ??++ |
| Betacyclodextrin | ??10.0 | ??88 | ??＜30 | ??＜10 | ??++ |
| Poloxamer | ??10.0 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium | ??10.0 | ??86 | ??＜30 | ??＜10 | ??+++ |
| Sodium lauryl sulphate | ??10.0 | ??83 | ??＜30 | ??＞10 | ??+++ |
| Stearic acid | ??10.0 | ??76 | ??＞30 | ??＞10 | ??+++ |
| Sodium stearate | ??10.0 | ??77 | ??＞30 | ??＞10 | ??+++ |
| Glycerin gelatine | ??10.0 | ??74 | ??＞30 | ??＞10 | ??+++ |
| Lac | ??10.0 | ??76 | ??＞30 | ??＞10 | ??+++ |
The group practices of table 4 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ??50 | ??85 | ??＜30 | ??＜10 | ??++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ??50 | ??86 | ??＜30 | ??＜10 | ??++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ??50 | ??81 | ??＜30 | ??＞10 | ??++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ??50 | ??79 | ??＜30 | ??＞10 | ??+ |
The group practices of table 5 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ??25 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ??25 | ??91 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ??25 | ??89 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ??25 | ??87 | ??＜30 | ??＞10 | ??++ |
The group practices of table 6 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | ??10 | ??93 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 1 | ??10 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | ??10 | ??90 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | ??10 | ??86 | ??＜30 | ??＞10 | ??+++ |
The group practices of table 7 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ??50 | ??93 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ??50 | ??94 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ??50 | ??89 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ??50 | ??87 | ??＜30 | ??＞10 | ??++ |
The group practices of table 8 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ??25 | ??95 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ??25 | ??95 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ??25 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ??25 | ??89 | ??＜30 | ??＜10 | ??++ |
The group practices of table 9 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | ??10 | ??93 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 5 | ??10 | ??94 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | ??10 | ??91 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | ??10 | ??88 | ??＜30 | ??＜10 | ??+++ |
The group practices of table 10 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ??50 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ??50 | ??91 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ??50 | ??89 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ??50 | ??82 | ??＜30 | ??＞10 | ??+++ |
The group practices of table 11 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ??25 | ??94 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ??25 | ??92 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ??25 | ??90 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ??25 | ??89 | ??＜30 | ??＜10 | ??+++ |
The group practices of table 12 medicine dry powder and mixed-matrix
(medicine dry powder: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | ??10 | 93 | ??＜30 | ??＜10 | ??+++ |
| Poloxamer: Polyethylene Glycol=1: 10 | ??10 | 93 | ??＜30 | ??＜10 | ??+++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | ??10 | 91 | ??＜30 | ??＜10 | ??+++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | ??10 | 92 | ??＜30 | ??＜10 | ??+++ |
1. can be seen by the result in the table: when being 1: 1 when medicine dry powder with the ratio of substrate, its rounding rate, the ball method of double differences is different and index such as hardness is all undesirable, and dissolve scattered time limit institute is influenced not obvious.
2. when the ratio of medicine dry powder and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when the ratio of medicine dry powder and substrate is 1: 9, though the rounding rate, the ball method of double differences is different and index such as hardness has raising, and is not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly is out of shape, " ++ " expression distortion of firmly pressing, and " +++" expression is indeformable by it.
Claims (6)
1. pharmaceutical composition fleabane and earthworm dripping pill that is used for the treatment of the cerebral infarction that obstruction of collaterals by blood stasis causes, with the extract that contains fresh Pheretima, Herba Erigerontis etc. 2 flavor Chinese medicine active pharmaceutical ingredients is raw material, be prepared from pharmaceutically suitable carrier as substrate, wherein:
1.1 raw material---with g or kg is unit, calculates according to weight, gets 6 parts of fresh Pheretimas, 5 parts of Herba Erigerontiss, more than two flavors make the extract that contains 2 flavor Chinese medicine active pharmaceutical ingredients such as fresh Pheretima and Herba Erigerontis in advance;
1.2 substrate---substrate---Polyethylene Glycol
(1000,2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac, the mixture of one or more in above-mentioned pharmaceutically suitable carrier;
1.3 proportioning---with g or kg is unit, by weight, and medicine dry powder: substrate=1: 1～1: 9.
2. fleabane and earthworm dripping pill as claimed in claim 1, it is characterized in that the described extract that contains 2 flavor Chinese medicine active pharmaceutical ingredients such as fresh Pheretima and Herba Erigerontis makes through following method: with g or kg is unit, according to the weight portion meter, get 6 parts of fresh Pheretimas, 5 parts of Herba Erigerontiss, more than two the flavor medical materials, fresh Pheretima adds water logging to be washed 1～2 hour, after cleaning, smashed to pieces, homogenate 10～15 minutes, with the sodium chloride solution extraction of 0.1mol/L 6 hours, centrifugal, get supernatant, cold drying, it is standby to get Pheretima extract.Get Herba Erigerontis, use Diluted Alcohol heating and refluxing extraction 50 minutes, filter, filtrate decompression is concentrated into the thick paste that relative density is 1.25～1.35 (60 ℃), hydro-oxidation sodium filters to alkalescence, and filtrate adds hydrochloric acid and regulates pH value to 2.0, filter, precipitate, is drained to neutral with hot water wash, after a small amount of Diluted Alcohol gradation washing, add an amount of thermosol of ethanol, add medicinal activated carbon and decolour in right amount, filter, filtrate concentrates, place, separate out amorphous yellow powder, filter drying, with the Pheretima extract mixing, be dried and crushed into dry powder promptly through decompression (0.1Mpa) low temperature (60 ℃) again.
3. fleabane and earthworm dripping pill as claimed in claim 1 is characterized in that: described substrate is the mixture of Polyethylene Glycol and polyoxyethylene stearate 40 esters or Polyethylene Glycol and poloxamer or Polyethylene Glycol and carboxymethyl starch sodium or Polyethylene Glycol and betacyclodextrin; With g or kg is unit, and by weight, its mixed proportion is polyoxyethylene stearate 40 esters: Polyethylene Glycol or poloxamer: Polyethylene Glycol or carboxymethyl starch sodium: Polyethylene Glycol or betacyclodextrin: Polyethylene Glycol=1: 1～1: 10.
4. as claim 1 or 3 described any fleabane and earthworm dripping pills, it is characterized in that: the mixed proportion of described drug extract and substrate is 1: 1～1: 5.
5. the preparation method of a fleabane and earthworm dripping pill is characterized in that being made of following process:
5.1 with g or kg is unit, calculates according to weight, gets 6 parts of fresh Pheretimas, 5 parts of Herba Erigerontiss, more than two flavors to make the extract that contains 2 flavor Chinese medicine active pharmaceutical ingredients such as fresh Pheretima and Herba Erigerontis in advance standby;
5.2 substrate---substrate---substrate---Polyethylene Glycol
(1000,2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac, the mixture of one or more in above-mentioned pharmaceutically suitable carrier;
5.3 proportioning---with g or kg is unit, by weight, and medicine dry powder: substrate=1: 1～1: 9.
5.4, accurately take by weighing medicine dry powder and substrate according to the given ratio of prescription, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing medicine dry powder and substrate and/or emulsion and/or suspension;
5.5 adopt homemade or general drop pill machine, and adjust the temperature control system of drop pill machine, make the water dropper temperature heating of drop pill machine and remain on 50 ℃～90 ℃, the temperature cooling of condensing agent also remains on-5 ℃～40 ℃;
5.6 when treating in dropping-pill machine head and the condensation column that the temperature of condensing agent reaches desired state of temperature respectively, to contain in the fused solution and/or emulsion and/or suspension of medicine dry powder and substrate, place in the water dropper jar of drop pill machine, splash in the condensing agent and shrink shaping promptly.
6. as the preparation method of fleabane and earthworm dripping pill as described in the claim 5, it is characterized in that: described condensing agent be methyl-silicone oil or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100086200A CN100358500C (en) | 2005-02-28 | 2005-02-28 | Fleabane and earthworm dripping pill and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100086200A CN100358500C (en) | 2005-02-28 | 2005-02-28 | Fleabane and earthworm dripping pill and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682818A true CN1682818A (en) | 2005-10-19 |
| CN100358500C CN100358500C (en) | 2008-01-02 |
Family
ID=35262437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100086200A Expired - Fee Related CN100358500C (en) | 2005-02-28 | 2005-02-28 | Fleabane and earthworm dripping pill and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100358500C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150250830A1 (en) * | 2013-03-10 | 2015-09-10 | Charles W. Moro | Novel Preparation for the Treatment of Itching and Inflammation Associated with Psoriasis and Other Topical Skin Maladies |
-
2005
- 2005-02-28 CN CNB2005100086200A patent/CN100358500C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150250830A1 (en) * | 2013-03-10 | 2015-09-10 | Charles W. Moro | Novel Preparation for the Treatment of Itching and Inflammation Associated with Psoriasis and Other Topical Skin Maladies |
| US9585919B2 (en) * | 2013-03-10 | 2017-03-07 | Charles W Moro | Preparation for the treatment of itching and inflammation associated with psoriasis and other topical skin maladies |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100358500C (en) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1634476A (en) | Chinese ephedra and almond containing cough stopping dripping pills and its preparing process | |
| CN1297254C (en) | Drop pills containing bear gall and tendril-leaved fritillary bulb and preparation method thereof | |
| CN1307977C (en) | Propolis dripping pills for treating toothache and its preparation method | |
| CN1634509A (en) | Yitongshu drop pill for treating pain and its preparation method | |
| CN1634452A (en) | Yin-nourishing lung-heat clearing drop pills | |
| CN1307976C (en) | Thorax comforting drop pills for treating cardiopathy and preparation method thereof | |
| CN1634478A (en) | Tendril-leaved fritillary bulb loquat drop pills and preparation method thereof | |
| CN1679676A (en) | Six-component saf-flower drops and preparation thereof | |
| CN1682818A (en) | Fleabane and earthworm dripping pill and its preparing method | |
| CN1686389A (en) | Danhong drip pill prepared from salvia root and carthamus and its preparation method | |
| CN1686342A (en) | Herminium drip pill and its preparation method | |
| CN1301107C (en) | Xiyanping drop pills of possessing function of clearing away heat and toxic materia and preparation method | |
| CN1307975C (en) | Safflower drop pills and preparation method thereof | |
| CN1316957C (en) | Yam rhizoma drop-pill and its preparation method | |
| CN1634511A (en) | Fengshining drop pill for treating rheumatism and its preparation method | |
| CN1301095C (en) | 'Yinchai' drop pills for treating cold, fever and cough and preparation method | |
| CN1307978C (en) | Drop pill for diminishing inflammation in four seasons and its preparation method | |
| CN1301094C (en) | Throat pain relieving anti-inflammation drop pills for treating oral disease and preparation method thereof | |
| CN1679675A (en) | Chuanhuang anti-inflammation drops for clearing away heat and detoxicating, and preparation thereof | |
| CN1698822A (en) | 'Gansu' dripping pills for treating hepatitis and its preparation method | |
| CN1634490A (en) | Drop pills for treating throat diseases and preparation method thereof | |
| CN1679669A (en) | Polygala dropping balls and preparation thereof | |
| CN1686388A (en) | Kangai drip pill for treating tumour, hepatitis B and its preparation method | |
| CN1679671A (en) | Compound berberine dropping ball and preparation thereof | |
| CN1634485A (en) | Drop pills for treating apoplexy diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080102 Termination date: 20110228 |